keynote-189: clinical implications in patients with low (1-49%) tumor pd-l1 expression (bmic-032)
Published 6 years ago • 246 plays • Length 6:16Download video MP4
Download video MP3
Similar videos
-
6:32
keynote-189: clinical implications in patients with less than 1% tumor pd-l1 expression (bmic-033)
-
7:58
keynote-189: clinical implications for high tumor pd-l1 expression (bmic-031)
-
13:06
keynote-189: key summary of a practice-changing trial in advanced non-squamous nsclc (bmic-030)
-
4:53
chemo-immunotherapy in nsclc: the keynote-189 trial
-
8:13
has the keynote-189 trial defined a clear standard of care? (bmic-022)
-
11:05
keynote-042: should pembrolizumab replace chemo for broader population with adv. nsclc? (bmic-038)
-
4:21
optimizing use of the keynote-189 regimen in mnsclc
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
5:43
advanced-stage nsclc: keynote-189’s role in treatment
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
2:11
edward b. garon, md, on the implications of keynote-189
-
5:33
significance of keynote-189 in nsclc
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
1:08
dr. stinchcombe on the keynote-189 trial in lung cancer
-
1:55
dr. kim on the keynote-189 trial in metastatic nsclc
-
4:52
the keynote-407 trial in metastatic squamous nsclc
-
2:02
keynote-189: chemo plus pembrolizumab for nsclc
-
3:03
keynote-189 update: 4-year follow-up of fl pembro chemo metastatic nsclc